Abstract
This study aimed to describe the prevalence and predictors of a positive VIA (visual inspection with acetic acid) cervical cancer screening test in women living with human immunodeficiency virus (HIV). We retrospectively analysed data from women aged ≥15 who accessed VIA screening from health facilities in the Lubombo and Manzini regions of Eswatini. Sociodemographic and clinical data from October 2020 to June 2023 were extracted from the client management information system. VIA screening outcome was categorised into negative, positive, or suspicious. A logistic regression model estimated the adjusted odds ratio (AOR) of the predictors of a positive VIA screen at p<0.05 with 95% confidence intervals. Of 23,657 participants, 60.8% (n=14,397) were from the Manzini region. The mean age was 33.3 years (standard deviation 7.0), and 33% (n=7,714) were first-time screens. The prevalence of a positive VIA was 2.6% (95% CI: 2.2%, 3.0%): 2.8% (95% CI: 2.2%, 3.5%) in Lubombo and 2.4% (95% CI: 2.0%, 2.9%) in Manzini (p=0.096). Screening at mission-owned (OR 1.40; p=0.001), NGO-owned (OR 3.08; p<0.001) and industrial/workplace-owned health facilities (OR 2.37; p=0.044) were associated with positive test results compared to government-owned health facilities, and being within the 35–44 age group (OR 1.26; p=0.017) compared to 25-34 years age group was a positive predictor of a positive VIA screen. Negative predictors of positive VIA test were: being on anti-retroviral therapy (ART) for 5-9 years (OR 0.76; p=0.004) and ≥10 years (OR 0.66; p=0.002) compared to <5 years; and having an undetectable viral load (OR 0.39; p<0.001) compared to unsuppressed. Longer duration on ART and an undetectable viral load reduced the odds, while middle-aged women and screening at non-public health facilities increased the odds of a positive VIA screen.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The Support Eswatini Achieve and Sustain HIV Epidemic Control (SEASEC) Program is supported by the U.S President's Emergency Plan for AIDS Relief through the Centers for Disease Control and Prevention (Co-operative Agreement No.:NU2GGH002294), implemented by Georgetown University in collaboration with the Government of the Kingdom of Eswatini. The funders had no role in the conceptualization of the study, study design, data collection and analysis, decision to publish and preparation of the manuscript.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study is covered under the protocol approved by the Eswatini Health and Human Research Review Board (EHHRRB 116/2022) for Georgetown University to analyse program data for dissemination. The EHHRRB also approved a waiver of informed consent by patients. Additional approval has been obtained from the Georgetown University Institutional Review Board (GU - IRB) (STUDY 00006034) and the United States Centers for Disease Control (CDC) (Accession #: CGH-ESW-9/14/23-15af6). Anonymised data were used to ensure confidentiality and the EHHRRB also approved an application for a waiver of written informed consent from participants since the data is from routine care extracted from the electronic medical records.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
The data underlying this research is not readily available for sharing at the moment but will be made available soon as relevant approvals are obtained.
